A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer

© 2024 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

¹Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
²Department of Radiology, Weill Cornell Medical Center, New York, New York;
³Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York;
⁴Janssen Research & Development, LLC, Spring House, Pennsylvania;
⁵Invicro, LLC, Boston, Massachusetts;
⁶Memorial Sloan Kettering Cancer Center, New York, New York;
⁷Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; and
⁸Department of Medicine, Weill Cornell Medicine, New York, New York

For correspondence or reprints, contact Michael J. Morris (morrism{at}mskcc.org).